Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Phase 2 Not yet recruiting 48 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of neoadjuvant treatment with Tislelizumab combined with chemotherapy for initially unresectable N2/III non-small cell lung cancer.

Timeline

Start: 2024-09-20
Primary completion: 2028-09-08
Completion: 2028-09-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tislelizumab	Monoclonal antibody	200 mg	—

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications